KLASKIN CHRISTINE M

SEC source: 0000950170-25-091632 · ownership.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,478

F1 · security: Reflects the executive's 2024 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on July 18, 2025.

F2 · price: $4.47 was the fair market value of Agenus Common Stock on June 18, 2025, the stock issuance date.

SEC source: 0000950170-25-088491 · ownership.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,250

Underlying: Common Stock · 7,250 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on May 28, 2026 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0000950170-24-127936 · ownership.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-11-14

F1 · derivative.exercise_date: Represents a one-time retention award comprised of options to purchase common stock, which were granted to certain key employees, including our executive officers. These options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on November 15, 2025.

SEC source: 0000950170-24-074840 · ownership.xml · derivative · entry 3

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,125

Underlying: Common Stock · 750 shares

Expires 2034-01-26

F3 · derivative.exercise_date: Options were granted on January 26, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 26, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 62,500 Stock Options with an exercise price of $0.66.

SEC source: 0000950170-24-074840 · ownership.xml · derivative · entry 2

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 6,250 shares

Expires 2034-01-16

F2 · derivative.exercise_date: Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 125,000 Stock Options with an exercise price of $0.61.

SEC source: 0000950170-24-074840 · ownership.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,642

Underlying: Common Stock · 10,642 shares

Expires 2034-01-16

F1 · derivative.exercise_date: Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. These options vest as to 50% of the underlying shares on June 27, 2024 and 50% of the underlying shares on September 27, 2024. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 212,840 Stock Options with an exercise price of $0.61.

SEC source: 0000899243-23-001321 · doc4.xml · derivative · entry 2

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,916

Underlying: Common Stock · 162,916 shares

Expires 2033-01-05

F3 · derivative.exercise_date: Option was granted on January 5, 2023 and awarded in accordance with the 2019 Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.

SEC source: 0000899243-23-001321 · doc4.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,937

F1 · security: Reflects the executive's 2022 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.

F2 · price: $2.45 was the fair market value of Agenus Common Stock on January 5, 2023, the stock issuance date.

SEC source: 0000899243-22-004868 · doc4.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,643

F1 · security: Reflects the executive's 2021 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 6-month lockup restriction with 25% of the award released on the 3-month anniversary of the issuance date and 75% of the award released on the 6-month anniversary.

F2 · price: $2.51 was the fair market value of our Common Stock on February 2, 2022, the stock issuance date.

SEC source: 0000899243-22-000624 · doc4.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: One-third of the stock options vest on the one-year anniversary of the date of grant, with the remainder vesting in equal quarterly installments thereafter; provided that the Reporting Person maintains a service relationship with the Issuer through each such vesting date.

SEC source: 0000899243-21-035843 · doc4.xml · derivative · entry 3

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,563 shares

Expires 2021-09-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-035843 · doc4.xml · nonDerivative · entry 2

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,056

F3 · price: Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.47 to $6.52. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-035843 · doc4.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021.

F2 · balance_after: The number of shares beneficially owned by the reporting person does not reflect 998 shares that were incorrectly reported on prior Form 4s.

SEC source: 0000899243-21-027316 · doc4.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests over a four-year period, with 1/3 of Option vesting on December 17, 2022, and the balance vesting in eight equal quarterly installments thereafter.

SEC source: 0000899243-21-014725 · doc4.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,611

F1 · security: All Agenus employees were given the option to receive their 2020 bonus awards in cash or Agenus stock. Dr. Armen, Dr. Buell and Ms. Klaskin have all chosen to receive their entire 2020 bonus award in Agenus stock rather than cash. The stock issued is fully-vested on the date of issuance, but is subject to a 6-month lockup restriction.

F2 · price: $2.87 is the fair market value of our Common Stock on April 2, 2021, the stock issuance date.

SEC source: 0001745285-20-000044 · primary_doc.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter (provide Ms. Klaskin maintains a service relationship with the Company through each such vesting date).

SEC source: 0001745285-20-000012 · primary_doc.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2030-06-15

F1 · derivative.exercise_date: Option was granted on June 15, 2020 in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Option vests in full on June 15, 2021.

SEC source: 0000899243-19-030109 · doc4.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2029-12-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Option vests over a three-year period, with 1/3 of Option vesting on December 24, 2020, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001745285-19-000017 · primary_doc.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,537

Underlying: Common Stock · 4,537 shares

Expires 2029-11-05

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Option vests over a three-year period, with 1/3 of Option vesting on November 5, 2020, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001745285-19-000012 · primary_doc.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · Vice President Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,667

Underlying: Common Stock · 14,667 shares

Expires 2029-07-23

F1 · derivative.exercise_date: Stock option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan and is eligible to vest, if at all, in a single installment on June 30, 2022 based upon the Company stock price performance. Amount shown reflects the target award. The ultimate award size can range between 0% and 150% of target based on the actual average stock price achieved at the end of the performance period.

SEC source: 0000899243-19-017847 · doc4.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · V.P. Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2029-01-01

F1 · derivative.exercise_date: Option was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19, 2019. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. Option vests over a three year period, with 1/3 of Option vesting on January 1, 2020, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001288123-18-000010 · primary_doc.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · VP Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,150

Underlying: Common Stock · 83,150 shares

Expires 2018-03-02

F1 · derivative.exercise_date: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001288123-18-000022 · primary_doc.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · VP Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,150

Underlying: Common Stock · 83,150 shares

Expires 2028-03-02

F2 · security: Amendment filed to correct previously reported expiration date of the award.

F1 · derivative.exercise_date: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Options awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on march 2, 2019 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001288123-17-000041 · primary_doc.xml · nonDerivative · entry 2

KLASKIN CHRISTINE M · CIK 0001288123 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,333

F2 · kind: Represents sales of shares sold solely to cover Federal, state and local tax withholding requirements on the restricted shares settled and were sold at prices ranging between $3.49 and $3.43 per share.

F2 · price: Represents sales of shares sold solely to cover Federal, state and local tax withholding requirements on the restricted shares settled and were sold at prices ranging between $3.49 and $3.43 per share.

SEC source: 0001288123-17-000041 · primary_doc.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,943

F1 · shares: Represents settlement of restricted shares awarded on July 1, 2015.

SEC source: 0001378706-17-000054 · wf-form4_149576354805036.xml · derivative · entry 2

KLASKIN CHRISTINE M · CIK 0001288123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2026-04-05

F1 · kind: Following the completion of the Merger and pursuant to the Merger Agreement between the Company and Tecogen Inc. dated November 1, 2016 and as amended March 23, 2017, the Company's securities were converted to securities of the Tecogen Inc.

F1 · derivative.exercise_date: Following the completion of the Merger and pursuant to the Merger Agreement between the Company and Tecogen Inc. dated November 1, 2016 and as amended March 23, 2017, the Company's securities were converted to securities of the Tecogen Inc.

SEC source: 0001378706-17-000054 · wf-form4_149576354805036.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Following the completion of the Merger and pursuant to the Merger Agreement between the Company and Tecogen Inc. dated November 1, 2016 and as amended March 23, 2017, the Company's securities were converted to securities of the Tecogen Inc.

SEC source: 0001288123-17-000024 · primary_doc.xml · nonDerivative · entry 2

KLASKIN CHRISTINE M · CIK 0001288123 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,512

F2 · kind: Represents exclusively, shares withheld by Agenus Inc. in respect of payment of the withholding tax liability upon the vesting of the restricted shares.

SEC source: 0001288123-17-000024 · primary_doc.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,245

F1 · kind: Represents settlement of vested restricted shares granted on July 1, 2015.

SEC source: 0001288123-17-000011 · primary_doc.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,500

Underlying: Common Stock · 72,500 shares

Expires 2027-03-31

F1 · derivative.exercise_date: Options vest one-third on the one-year anniversary of the grant date with the remainder vesting in equal quarterly installments provided the executive maintains a service relationship with the Company through each vesting date.

SEC source: 0000899243-16-029400 · doc4.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · VP Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,551

Underlying: Common Stock · 7,551 shares

Expires 2026-09-16

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Inventive Plan, and vests in one installment on the one-year anniversary of the grant date.